1. Home
  2. PCRX vs EVV Comparison

PCRX vs EVV Comparison

Compare PCRX & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.51

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Limited Duration Income Fund of Beneficial Interest

EVV

Eaton Vance Limited Duration Income Fund of Beneficial Interest

HOLD

Current Price

$9.37

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
EVV
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2010
2003

Fundamental Metrics

Financial Performance
Metric
PCRX
EVV
Price
$22.51
$9.37
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$37.20
N/A
AVG Volume (30 Days)
579.3K
372.7K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$139.00
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$8.97
52 Week High
$27.99
$10.41

Technical Indicators

Market Signals
Indicator
PCRX
EVV
Relative Strength Index (RSI) 49.29 44.41
Support Level $22.57 $8.97
Resistance Level $23.94 $10.12
Average True Range (ATR) 0.79 0.13
MACD -0.07 0.03
Stochastic Oscillator 49.48 69.88

Price Performance

Historical Comparison
PCRX
EVV

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest

Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.

Share on Social Networks: